New Issue :: Current Drug Metabolism 18, Issue 3

Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation, recent developments for the identification of drug metabolites, adducts and preclinical and clinical summaries of marketed drugs.

cdm

Articles from the journal Current Drug Metabolism 18, Issue 3:

               For details on the articles, please visit this link :: http://bit.ly/2rM5ccL

 

 

Upcoming Thematic Issue – Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases & amp – Current Drug Metabolism

CMC- THEMATIC FLYER -Rajeev K. Singla

http://benthamscience.com/journals/current-drug-metabolism/special-issues/#top

Upcoming Thematic Issue – Drug Pharmacogenomics and Pharmacokinetics(PK)- Pharmacodynamics(PD)

CDM-THEMATIC FLYER -Ji-Fu Wei

http://www.eurekaselect.com/592/journal/current-drug-metabolism

New Issue :: Current Drug Metabolism 18, Issue 2

Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation, recent developments for the identification of drug metabolites, adducts and preclinical and clinical summaries of marketed drugs.

cdm

Articles from the journal Current Drug Metabolism 18, Issue 2:


For details on the articles, please visit this link :: 
http://bit.ly/2oZXgrl

Upcoming Thematic Issue – Topical Collection on Major Psychosis: Current findings on Drug Metabolism

CDM-THEMATIC FLYER -Gustavo Scola

http://benthamscience.com/journals/current-drug-metabolism/

Upcoming Thematic Issue – Traditional Systems of Medicine and Phytotherapy in Neurological Disorders

CDM THEMATIC FLYER- Arman Zargaran; PharmD, PhD

http://benthamscience.com/journals/current-drug-metabolism/

Article by Disease – “Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism”

Article by Disease on “Metabolic Disorders”

Abstract:

Introduction: The kynurenine pathway includes several neuroactive compounds, including kynurenic acid, picolinic acid, 3-hydroxykynurenine and quinolinic acid. The enzymatic cascade of the kynurenine pathway is tightly connected with the immune system, and may provide a link between the immune system and neurotransmission.

Main Areas Covered: Alterations in this cascade are associated with neurodegenerative, neurocognitive, autoimmune and psychiatric disorders, such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, migraine or schizophrenia.

Highlights: This review highlights the alterations in this metabolic pathway in the physiological aging process and in different disorders. A survey is also presented of therapeutic possibilities of influencing this metabolic route, which can be achieved through the use of synthetic kynurenic acid analogues, enzyme inhibitors or even nanotechnology.

Read more: http://www.eurekaselect.com/node/138027/article 

Upcoming Thematic Issue – Recent Development of Drug Delivery systems for improving Bioavailability and Pharmacokinetics

cbm-thematic-flyer-thao-tran

http://www.eurekaselect.com/592/journal/current-drug-metabolism

Highlighted Article Flyer for the journal “Current Drug Metabolism”

cdm-articles_18-catarina-pinto-reis

http://benthamscience.com/journals/current-drug-metabolism/

Most Accessed Article – “Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450”

Journal: Current Drug Metabolism

Author(s): Ruirui Yang, Zhiqiang Luo, Yang Liu, Mohan Sun, Ling Zheng, Yingying Chen, Yanping Li, Hao Wang, Lingzhu Chen, Ming Wu and Huihui Zhao

cdm

Abstract:

Background: Angiotensin receptor blockers (ARBs) are the most recent class of agents for the treatment of hypertension. However, ARBs may cause a low incidence of headache, upper respiratory infection, back pain, muscle cramps, fatigue, dizziness, and many other side effects. In some cases, such toxicity is associated with pharmacokinetic alterations.

Methods: The cytochrome P450 (CYP) enzyme system plays an important role in a lot of clinically important pharmacokinetic drug interactions. To identify relevant studies on drug-drug and food-drug pharmacokinetic interactions with the ARBs, a literature search of Google Scholar was performed from January 1994 to June 2015, with the following keywords: ‘losartan’, ‘valsartan,’ ‘candesartan,’ ‘irbesartan,’ ‘telmisartan,’ ‘eprosartan,’ ‘olmesartan,’ and ‘azilsartan’, combined with the keyword ‘pharmacokinetic interactions’ and ‘CYP’.

Results: Based on the literatures published, it has been demonstrated that pharmacokinetic interactions of losartan with other agents are mainly via CYP2C9- and CYP3A4-mediated, the role played by CYP enzyme system in the metabolism of valsartan, candesartan, irbesartan, and azilsartan appears modest, and cytochrome P450 system has no influence on the metabolism of telmisartan, eprosartan, olmesartan. Therefore, according to these pharmacokinetic findings, no dosage adjustment is recommended when eprosartan, telmisartan and olmesartan are combined with other pharmacological agents in patients with hypertension.

Conclusion: This review summarize the available data on cytochrome P450 – related drug–drug interactions reported in the literature for the eight ARBs. Knowledge of the pharmacokinetic properties of the ARBs should allow the avoidance of the majority of drug interactions without compromising therapeutic benefits.

To access the article, please visit: http://benthamscience.com/journals/current-drug-metabolism/volume/17/issue/7/page/681/